RxDoctor Payments Data

Andre Olivier, MD

Cardiovascular Disease · Lebanon, TNNPI 1558386771

Payments from drug & device makers

$34,021in general payments, 2019–2025

Across 624 payments — averaging $54.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$12K
  • E.r. Squibb & Sons, L.L.C.$9K
  • Boston Scientific$3K
  • Medtronic$3K
  • Actelion Pharmaceuticals US, Inc.$2K
  • Boehringer Ingelheim$1K
  • plus $5K from 26 others

What the payments were for

  • Consulting fees$2,3007%
  • Speaking & faculty fees$16,68549%
  • Travel & lodging$1,0463%
  • Food & beverage$13,96841%
  • Education$220%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,021 in reported general payments places this provider in the 80th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$230,644
Medicare patients
1,162
Services billed
3,621

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,064$1,079,246
EntrestoSacubitril/Valsartan147$177,212
Repatha SureclickEvolocumab150$144,355
XareltoRivaroxaban128$127,302
JardianceEmpagliflozin66$76,409
BrilintaTicagrelor37$30,122
Praluent PenAlirocumab28$18,980
VerquvoVericiguat21$15,466
FarxigaDapagliflozin Propanediol14$15,259
Ranolazine ErRanolazine62$14,152
Metoprolol Succinate783$10,124
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide310$8,425
Atorvastatin Calcium674$8,302
Isosorbide Mononitrate ErIsosorbide Mononitrate393$7,324
Rosuvastatin Calcium472$6,956

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$11,641$1,079,2461,064 claims
NovartisEntresto$274$177,212147 claims
Johnson & JohnsonXarelto$883$127,302128 claims
Boehringer IngelheimJardiance$1,050$76,40966 claims
AstraZenecaBrilinta, Farxiga$257$45,38151 claims
MerckVerquvo$347$15,46621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 429 cardiovascular disease providers in Tennessee.

Other cardiovascular disease in Lebanon

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →